stoxline Quote Chart Rank Option Currency Glossary
  
ImmunoPrecise Antibodies Ltd. (IPA)
0.4308  0.009 (2.13%)    02-18 16:00
Open: 0.4199
High: 0.449
Volume: 518,016
  
Pre. Close: 0.4218
Low: 0.41
Market Cap: 20(M)
Technical analysis
2025-02-18 4:44:42 PM
Short term     
Mid term     
Targets 6-month :  0.84 1-year :  1.07
Resists First :  0.72 Second :  0.92
Pivot price 0.46
Supports First :  0.4 Second :  0.34
MAs MA(5) :  0.44 MA(20) :  0.49
MA(100) :  0.48 MA(250) :  0.87
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  9.7 D(3) :  9
RSI RSI(14): 42.7
52-week High :  2.43 Low :  0.32
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ IPA ] has closed above bottom band by 18.2%. Bollinger Bands are 35.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.45 - 0.45 0.45 - 0.46
Low: 0.4 - 0.41 0.41 - 0.41
Close: 0.43 - 0.43 0.43 - 0.44
Company Description

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

Headline News

Mon, 27 Jan 2025
ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture - Business Wire

Mon, 27 Jan 2025
ImmunoPrecise Antibodies Raises $7M, Eliminates Debt Through Strategic Financing - StockTitan

Mon, 27 Jan 2025
ImmunoPrecise Antibodies Ltd. (IPA) Unveils AI-Developed GLP-1 Therapies for Type 2 Diabetes and Obesity, Pioneering New Frontiers in Biotech Innovation - Yahoo Finance

Wed, 22 Jan 2025
ImmunoPrecise Unveils AI-Designed GLP-1 Therapy Alternative with Transdermal Delivery Potential - StockTitan

Wed, 22 Jan 2025
IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment - Business Wire

Mon, 23 Dec 2024
ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 46 (M)
Shares Float 29 (M)
Held by Insiders 5.2 (%)
Held by Institutions 4.1 (%)
Shares Short 359 (K)
Shares Short P.Month 104 (K)
Stock Financials
EPS -0.75
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.08
Profit Margin -116 %
Operating Margin -46.4 %
Return on Assets (ttm) -13.7 %
Return on Equity (ttm) -65.9 %
Qtrly Rev. Growth -0.5 %
Gross Profit (p.s.) 0.26
Sales Per Share 0.52
EBITDA (p.s.) -0.27
Qtrly Earnings Growth 0 %
Operating Cash Flow -8 (M)
Levered Free Cash Flow -3 (M)
Stock Valuations
PE Ratio -0.58
PEG Ratio 0
Price to Book value 0.39
Price to Sales 0.81
Price to Cash Flow -2.55
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android